Patient disposition and baseline characteristics
antiseizure, seizure, Epilepsy, epilepsy
MAY, EPILEPSY, EPILEPSY
This open‐label trial was conducted between May 2017 and June 2019; 103 patients were enrolled and completed the trial (SS; 77 from Europe, 26 from North America). Most patients (96 [93.2%]) were White. Fifty‐five patients were ≥8 to <17 years of age (cohort 1) and 48 were ≥1 month to <8 years of age (cohort 2). Patients had a mean age of 8.6 years, and 57 (55.3%) were female (Table Baseline demographics, medical conditions, epilepsy characteristics, concomitant ASMs, and target infusion duration (SS‐IV)Abbreviations: ASM, antiseizure medication; IV, intravenous; SD, standard deviation; SS‐IV, intravenous Safety Set.Trial SP848 or EP0034.n = 54.n = 102.Patients could have more than one response in a classification level and/or category; seizure types are listed per the International League Against Epilepsy 1981 classification, with the newer terminology provided in parentheses.Concomitant medications are medications taken on ≥1 day in common with IV lacosamide during the treatment period.Lacosamide was reported as a concomitant ASM in patients who replaced one of their two daily oral doses with IV lacosamide.